Home/ Stocks/ LRMR

Larimar Therapeutics, Inc. Common Stock

LRMR XNAS

$4.57 +0.00 (+0.00%) ▲ 15-min delayed

Open

N/A

High

N/A

Low

N/A

Volume

N/A

Market Cap

$486.17M

About Larimar Therapeutics, Inc. Common Stock

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 71 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$0	$-165,673,000	N/A
FY 2025	$0	$-165,673,000	N/A
Q3 2025	$0	$-47,712,000	$-0.61
Q2 2025	$0	$-26,182,000	$-0.41

TickerDaily Coverage

Why Is Larimar Therapeutics, Inc. Common Stock (LRMR) Stock Up 43.0% Today?

Market News David Brooks · Feb 25, 2026

Larimar Therapeutics (LRMR) stock rocketed 43.0% to $5.2368 on massive volume following securities...

View All Coverage →

Get LRMR Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Larimar Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.